Here are the DEF 14A proxy statements from XBiotech Inc (XBIT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow XBIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIT filings page.
XBiotech Inc. asked shareholders to vote at its November 24, 2026 virtual annual meeting on five director nominees, ratification of Whitley Penn LLP as auditor for the fiscal year ending December 31, 2026, and advisory approval of named executive compensation. The Board recommends voting for all three proposals. Shareholders of record on September 25, 2026 were eligible to vote; 30,487,731 common shares were outstanding on that date.
The 2025 compensation table reports $30,134,204 in total compensation for John Simard, former President and CEO, including $17,341,326 in severance, $8,530,442 in bonuses and $3,000,000 in option awards. Dr. Sushma Shivaswamy, interim CEO and Chief Scientific Officer, had total compensation of $570,992, and Director of Finance Angela Hu had total compensation of $245,419. Shivaswamy’s annual salary increased from $450,000 to $750,000 while she served in those roles.